fashion -WSS

fashion

author：focus 2025-09-30 00:46:45 - browse：4478

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： House panel takes first step toward fixing drug shortages

explore

WSS

Transgender sports debate: Physicians say bans are health issue

Assistant physicians can help address the primary care shortage

How the messy conversation about Dolly changed bioethics

FDA panel to weigh safety of artificial wombs for preterm births

Patients, doctors press FTC to beef up hospital merger scrutiny

White House drug czar issues call for 'recovery

focus

fashion

focus

Guidelines to prevent youth baseball injuries need more muscle

Type 2 diabetes prevention programs work at large scale: study

Medical records are filled with copy

Carbon Health diabetes program, a test of data

Drug repurposing or repositioning? The language matters

Transgender sports debate: Physicians say bans are health issue

In age of alternative facts, a scholarly course on calling out crap

NIH chief: government has fallen behind pharma on clinical trials

How one medical school became remarkably diverse

entertainment

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

People with substance use disorder deserve online privacy

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

What happened to the House vote on health price transparency?

Akili changes sales model for its ADHD video game treatment

FDA reorg will put new emphasis on investigations, sources say

focus

hotspot

explore

entertainment